31
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure

ORCID Icon, , , , , & show all
Received 26 Sep 2023, Accepted 05 May 2024, Published online: 15 May 2024
 

Acknowledgments

FD, SDB and LY performed the research. FD, SDB and LY designed the research study. BA, MC and JGG contributed essential reagents or tools. BB analyzed the data. FD, SDB and LY wrote the paper. Medical writing for this manuscript was assisted by MPIYP (MC Béné), Paris, France.

Disclosure statement

No potential competing interest was reported by the authors.

Additional information

Funding

This study was supported by the French National Drug Agency (ANSM), the French National Research Agency (ANR) (project CAPTOR PHUC-001) and TouCANANR Laboratory of Excellence, MSCA-ITN/ETN PIPgen (Project ID: 955534, salary for MC).
This work was funded by the Agence Nationale de la Recherche; Toucan ANR Laboratory of Excellence, MSCA-ITN/ETN PIPgen; Agence Nationale du Médicament et des produits de Santé (ANSM).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.